Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.53 USD | +1.70% | -3.62% | -.--% |
May. 14 | Kyverna Therapeutics Q1 Loss Narrows | MT |
May. 14 | Kyverna Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | 3.75M | Sales 2025 * | 5M | Capitalization | 540M |
---|---|---|---|---|---|
Net income 2024 * | -138M | Net income 2025 * | -197M | EV / Sales 2024 * | 91.9 x |
Net cash position 2024 * | 196M | Net cash position 2025 * | 138M | EV / Sales 2025 * | 80.4 x |
P/E ratio 2024 * |
-3.48
x | P/E ratio 2025 * |
-2.96
x | Employees | 96 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.27% |
1 day | +1.70% | ||
1 week | -3.62% | ||
1 month | -17.24% | ||
3 months | -53.88% |
Managers | Title | Age | Since |
---|---|---|---|
Peter Maag
CEO | Chief Executive Officer | 57 | 22-10-12 |
Ryan Jones
DFI | Director of Finance/CFO | 36 | 17-12-31 |
Dominic Borie
CTO | Chief Tech/Sci/R&D Officer | 61 | 19-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Beth Seidenberg
BRD | Director/Board Member | 67 | 18-08-31 |
Ian Clark
CHM | Chairman | 62 | 21-09-14 |
Dan Spiegelman
BRD | Director/Board Member | 65 | 21-03-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 12.53 | +1.70% | 416,934 |
24-05-30 | 12.32 | -3.98% | 255,511 |
24-05-29 | 12.83 | -3.02% | 814,431 |
24-05-28 | 13.23 | +1.77% | 404,360 |
24-05-24 | 13 | +4.59% | 192,988 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-.--% | 540M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+0.04% | 12.16B | |
+25.12% | 12.21B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- KYTX Stock